(Total Views: 644)
Posted On: 12/30/2023 5:07:14 AM
Post# of 148903
Not FDA approved so of course they would ignore the findings. Also the test was developed as a diagnostic for hepatitis b and c patients using an algorithm to determine effect. Patients with hepatitis b or c may be a very small subset of the patient population and it would be impossible to prove statistical significance.
The broader range of biomarkers we will be testing for will be valid across all groups and what we will be looking for is a reduction in those markers that are a hallmark of an overactive immune system. Because the FDA still thinks of leronlimab as an immunosuppressor we will almost certainly also test for a rise in CD8 T-cells and other factors that show a balanced immune response.
The broader range of biomarkers we will be testing for will be valid across all groups and what we will be looking for is a reduction in those markers that are a hallmark of an overactive immune system. Because the FDA still thinks of leronlimab as an immunosuppressor we will almost certainly also test for a rise in CD8 T-cells and other factors that show a balanced immune response.
(12)
(0)Scroll down for more posts ▼
